Introduction
Up to 50% of the cystic fi brosis (CF) population is colonized in the lungs at one point by Aspergillus species, most commonly Aspergillus fumigatus [1 -4] . A subset of CF patients with Aspergillus will develop allergic bronchopulmonary aspergillosis (ABPA), an immune-mediated sensitization to Aspergillus , typically by a systemic antibody response, resulting in worsening pulmonary function [5] . In addition, irrespective of their ABPA status, CF patients with chronic A. fumigatus colonization are at increased risk for hospitalization due to an exacerbation of their pulmonary condition as compared to those intermittently colonized or those who have never had A. fumigatus [6] . The role of antifungal therapy in CF patients colonized with Aspergillus spp. remains unclear.
A galactomannan assay (Bio-Rad Laboratories Platelia Aspergillus EIA) has been approved for use in conjunction stored frozen over a 2-year period from December 2007 to November 2009. All subjects were classifi ed according to their respiratory culture status in the previous 12 months; (1) chronic colonization ϭ Ն 2 positive cultures for Aspergillus species in a given year, (2) intermittent colonization ϭ 1 positive culture for Aspergillus spp. in a given year or a previous positive culture at any time, (3) never colonization ϭ no cultures positive for Aspergillus spp. [9] . We included the fi rst sera collected from all three sets of patients for comparison. Baseline demographic data at the time of serum collection was recorded and included; age, sex, forced expiratory volume in 1 second (FEV 1 ), lung transplant status, presence of allergic bronchopulmonary aspergillosis (ABPA) (defi ned by the treating physician in combination with increased IgE levels) [5] , pancreatic insuffi ciency status, cystic fi brosisrelated diabetes (CFRD) status and whether the patient was on systemic antifungal therapy or piperacillintazobactam.
The sera were tested for galactomannan using a onestage immunoenzymatic sandwich microplate assay (Bio-Rad Laboratories Platelia Aspergillus EIA). Positive, negative, and cut-off controls were incorporated in each assay. Optical density was read at 450 nm with a reference fi lter of 620 nm. The presence or absence of galactomannan antigen in the test sample was determined by calculation of the optical density index (ODI) defi ned as the optical density value of the patient specimen divided by the mean optical density of the wells containing cut-off control sera samples. An optical density index of Ն 0.5 was considered positive. Analysis of variance (ANOVA) was used to assess if there were signifi cant ODI differences between groups. For comparison of demographic characteristics, continuous variables were compared using a one-way ANOVA and proportions were compared using chi-square or Fisher ' s exact test.
Results
A total of 155 samples from 58 pediatric patients and 80 adult patients were tested. Patient characteristics are summarized in Table 1 . Patients in the intermittent group were older, a higher proportion of patients in the chronic group had ABPA and patients in the never group had a higher FEV 1 . There was very little piperacillin-tazobactam use which has been associated with false-positive serum galactomannan [10] . All 155 serum samples had an optical density index Ͻ 0.5 and were therefore considered negative for galactomannan. There was no difference in the mean optical density index between patients classifi ed as chronic Aspergillus (mean ϭ 0.24, range 0.14 -0.45), intermittent Aspergillus (mean ϭ 0.24, range 0.14 -0.45) and never Aspergillus (mean ϭ 0.24, range 0.14 -0.34) ( P ϭ 0.60) (Fig. 1) .
Discussion
To our knowledge, this is the fi rst study to evaluate the utility of measuring serum galactomannan in a CF patient population. We demonstrated that there is no difference in serum galactomannan levels in CF patients with chronic compared to intermittent or no colonization with Aspergillus . The results also indicate that the serum concentrations of galactomannan do not achieve the levels seen in invasive aspergillosis in traditional immunocompromised patient populations.
There are signifi cant differences in the pathophysiology of Aspergillus infection between cystic fi brosis and immunocompromised patients. The lungs of CF patients contain abnormally thick mucus which can entrap ubiquitous Aspergillus conidia and allow them to germinate. The large amount of antigen released by the fungi during active growth likely contributes to the development of allergic bronchopulmonary aspergillosis in CF [11] . Although anatomical barrier defects such as these may predispose Aspergillus to colonize the lungs of CF patients, an intact cellular immune function likely prevents the conidia from further invasion [12] . In immunocompromised patients, invasion of Aspergillus into the vasculature may occur, for example in those with a lack of circulating neutrophils. Recently, elegant in vitro and animal models of Aspergillus infection in the immunocompromised host have suggested that galactomannan is not detected in serum until Aspergillus hyphae have invaded the vascular endothelium [13, 14] .
Our study had several limitations. We had a relatively small sample size which may have limited our power to detect differences between the groups. Our study was cross-sectional rather than longitudinal. In addition, it is possible that galactomannan antigenemia in CF patients colonized with Aspergillus is intermittent, positive only at the time of positive sputum cultures, and would thus be more likely to be detected in a longitudinal study. Antigenemia may also be detected more frequently in patients with serially positive cultures rather than simply two or more positive cultures in a year. Finally, as bronchoscopies are not routinely done in our patient population, we did not have access to bronchoalveolar lavage samples and thus Aspergillus detection was limited to sputum samples for culture and serum samples for the galactomannan assay.
In summary, our fi ndings of uniformly negative serum galactomannan in CF patients is consistent with the theory that galactomannan is only detected in the blood when Aspergillus hyphae have invaded the endothelium. Despite high rates of Aspergillus airway colonization, CF patients have low rates of endothelial invasion and invasive disease due to intact immune function. 
